PDCD1 and neoplasm: They confirmed the safety and feasibility of in vivo molecular imaging of PD-1/PD-L1 using 18F-BMS-986192 and 89Zn-nivolumab; the tumor accumulation of 18F-BMS-986192 correlated with PD-L1 expression, while the uptake of 89Zn-nivolumab correlated with the expression of PD-1.